Lead Product(s): Tezepelumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AMG 157
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2021
In NAVIGATOR, tezepelumab demonstrated superiority across every primary and key secondary endpoint, compared to placebo, in a broad population of patients with uncontrolled asthma while receiving treatment with medium- or high-dose inhaled corticosteroids.